Replies to post #130320 on Biotech Values

[acgood]

DEB025 is so different from other HCV drug candidates that we should expect the data reporting to deviate from the standard industry metrics to some degree

That may be the case...I have no idea. But that language is the sort of slippery slope to false claims and excuses that we would criticize other companies for deploying.

[oc631]

Looking at alisporivir under current efficacy metrics makes this drug look quite underwhelming. Perhaps there's a slow building mechanism of action? The best drugs in the space knock the virus down below the LOD at 2-weeks with a 90%+ SVR rate.